The HER-2/neu gene and protein in breast cancer 2003: Biomarker and target of therapy

Oncologist

Volumn 8, Issue 4, 2003, Pages 307-325

  Ross, Jeffrey S ^a,b   Fletcher, Jonathan A ^c   Linette, Gerald P ^b,d   Stec, James ^b   Clark, Edward ^b   Ayers, Mark ^b   Symmans, W Fraser ^e   Pusztai, Lajos ^e   Bloom, Kenneth J ^f  

^a ALBANY MEDICAL COLLEGE   (United States)

^b MILLENNIUM PHARMACEUTICALS INC   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f US Labs   (United States)

Author keywords

FISH; IHC; Prognosis; Review; Trastuzumab

Indexed keywords

ADRENALIN; AMPHIREGULIN; ANTHRACYCLINE ANTIBIOTIC AGENT; BETA CELLULIN; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; METHOTREXATE; NEU DIFFERENTIATION FACTOR; ONCOPROTEIN; TAMOXIFEN; TRANSFORMING GROWTH FACTOR ALPHA; TRASTUZUMAB; TUMOR MARKER; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG;

BREAST CANCER; BREAST CARCINOMA; BREAST DISEASE; BREAST SARCOMA; CANCER CHEMOTHERAPY; CYTOSOL; DRUG RESPONSE; DRUG TARGETING; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; PAGET NIPPLE DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SERUM; SOUTHERN BLOTTING;

ADULT; AGE DISTRIBUTION; AGED; ANTIBODIES, MONOCLONAL; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; COMBINED MODALITY THERAPY; EDUCATION, MEDICAL, CONTINUING; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0042208398     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.8-4-307     Document Type: Review

References (194)

1. Stern DF, Heffernan PA, Weinberg RA. p185, a product of the neu proto-oncogene, is a receptor-like protein associated with tyrosine kinase activity. Mol Cell Biol 1986;6:1729-1740.
2. Karunagaran D, Tzahar E, Beerli RR et al. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 1996;15:254-264.
3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2:127-137.
4. Tzahar E, Waterman H, Chen X et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 1996;16:5276-5287.
5. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: correlation of relapse and survival with amplification of the Her-2/neu oncogene. Science 1987;235:177-182.
6. Berger MS, Locher GW, Saurer S et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988;48:1238-1243.
7. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedotype ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
8. Heintz NH, Leslie KO, Rogers LA et al. Amplification of the c-erbB-2 oncogene and prognosis of breast adenocarcinoma. Arch Pathol Lab Med 1990;114:160-163.
9. Wright C, Angus B, Nicholson S et al. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res 1989;49:2087-2090.
10. Tsuda H, Hirohashi S, Shimosato Y et al. Correlation between histologic grade of malignancy and copy number of c-erbB-2 gene in breast carcinoma. A retrospective analysis of 176 cases. Cancer 1990;65:1794-1800.
11. Borg A, Tandon AK, Sigurdsson H et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
12. Paik S, Hazan R, Fisher ER et al. Pathologic findings from the National Surgical Adjuvant Breast and Bowel project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 1990;8:103-112.
13. Battifora H, Gaffey M, Esteban J et al. Immunohistochemical assay of neu/c-erbB-2 oncogene product in paraffin-embedded tissues in early breast cancer: retrospective follow-up study of 245 stage I and II cases. Mod Pathol 1991;4:466-474.
14. Kallioniemi OP, Holli K, Visakorpi T et al. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-655.
15. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein over-expression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991;63:434-438.
16. Clark GM, McGuire WL. Follow-up study of HER-2/neu amplification in primary breast cancer. Cancer Res 1991;51:944-948.
17. Lovekin C, Ellis IO, Locker A et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer 1991;63:439-443.
18. McCann AH, Dervan PA, O'Regan M et al. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer. Cancer Res 1991;51:3296-3303.
19. Dykins R, Corbett IP, Henry JA et al. Long-term survival in breast cancer related to overexpression of the c-erbB-2 oncoprotein: an immunohistochemical study using monoclonal antibody NCL-CB11. J Pathol 1991;163:105-110.
20. Rilke F, Colnaghi MI, Cascinelli N et al. Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 1991;49:44-49.
21. Winstanley J, Cooke T, Murray GD et al. The long term prognostic significance of c-erbB-2 in primary breast cancer. Br J Cancer 1991;63:447-450.
22. O'Reilly SM, Barnes DM, Camplejohn RS et al. The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer. Br J Cancer 1991;63:444-446.
23. Paterson MC, Dietrich KD, Danyluk J et al. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer. Cancer Res 1991;51:556-567.
24. Toikkanen S, Helin H, Isola J et al. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow up. J Clin Oncol 1992;10:1044-1048.
25. Molina R, Ciocca DR, Tandon AK et al. Expression of HER-2/neu oncoprotein in human breast cancer: a comparison of immunohistochemical and western blot techniques. Anticancer Res 1992;12:1965-1971.
26. Noguchi M, Koyasaki M, Ohta N et al. c-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer. Cancer 1992;69:2953-2960.
27. Allred DC, Clark GM, Tandon AK et al. HER-2/neu node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992;10:599-605.
28. Babiak J, Hugh J, Poppema S. Significance of c-erbB-2 amplification in DNA aneuploidy. Analysis in 78 patients with node-negative breast cancer. Cancer 1992;70:770-776.
29. Tiwari RK, Borgen PI, Wong GY et al. HER-2/neu amplification and overexpression in primary human breast cancer is associated with early metastasis. Anticancer Res 1992;12:419-425.
30. Gusterson BA, Gelber RD, Goldhirsch A et al. Prognostic importance of c-erbB-2 expression in breast cancer. J Clin Oncol 1992;10:1049-1056.
31. Bianchi S, Paglierani M, Zampi G et al. Prognostic significance of c-erbB-2 expression in node negative breast cancer. Br J Cancer 1993;67:625-629.
32. Press MF, Pike MC, Chazin VR et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
33. Seshadri R, Firgaira FA, Horsfall DJ et al. Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer study group. J Clin Oncol 1993;11:1936-1942.
34. Descotes F, Pavy J-J, Adessi GL. Human breast cancer: correlation study between HER-2/neu amplification and prognostic factors in an unselected population. Anticancer Res 1993;13:119-124.
35. Giai M, Roagna R, Ponzone R et al. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441-1450.
36. Muss HB, Thor AD, Berry DA et al. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:1260-1266.
37. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-2365.
38. Hartmann LC, Ingle JN, Wold LE et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-2963.
39. Jacquemier J, Penault-Llorca P, Viens P et al. Breast cancer response to adjuvant chemotherapy in correlation with erbB2 and p53 expression. Anticancer Res 1994;14:2773-2778.
40. Marks JR, Humphrey PA, Wu K at al. Overexpression of p53 and HER-2/neu proteins as prognostic markers in early stage breast cancer. Ann Surg 1994;219:332-341.
41. Rosen PP, Lesser ML, Arroyo CD et al. Immunohistochemical detection of HER-2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer 1995;75:1320-1326.
42. Quenel N, Wafflart J, Bonichon F et al. The prognostic value of c-erbB2 in primary breast carcinomas: a study on 942 cases. Breast Cancer Res Treat 1995;35:283-291.
43. Sundblad AS, Pellicer EM, Ricci L. Carcinoembryonic antigen expression in stages I and II breast cancer: its relationship with clinicopathologic factors. Hum Pathol 1996;27;297-301.
44. O'Malley FP, Saad Z, Kerkvliet N et al. The predictive power of semiquantitative immunohistochemical assessment of p53 and c-erbB-2 in lymph node-negative breast cancer. Hum Pathol 1996;27:955-963.
45. Hieken TJ, Mehta RR, Shilkaitis A et al. Her-2/neu and p53 expression in breast cancer: valid prognostic markers when assessed by direct immunoassay, but not by immunochemistry. Proc Am Soc Clin Oncol 1996;15:A113.
46. Xing W-R, Gilchrist KW, Harris CP et al. FISH detection of HER-2/neu oncogene amplification in early onset breast cancer. Breast Cancer Res Treat 1996;39:203-212.
47. Dittadi R, Brazzale A, Pappagallo G et al. ErbB2 assay in breast cancer: possibly improved clinical information using a quantitative method. Anticancer Res 1997;17:1245-1247.
48. Fernandez Acenero MJ, Farina Gonzalez J, Arangoncillo Ballesteros P. Immunohistochemical expression of p53 and c-erbB-2 in breast carcinoma: relation with epidemiologic factors, histologic features and prognosis. Gen Diagn Pathol 1997;142:289-296.
49. Eissa S, Khalifa A, el-Gharib A et al. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for short-term prognosis in breast cancer. Anticancer Res 1997;17:3091-3097.
50. Charpin C, Garcia S, Bouvier C et al. c-erbB-2 oncoprotein detected by automated quantitative immunocytochemistry in breast carcinomas correlates with patients' overall and disease-free survival. Br J Cancer 1997;75:1667-1673.
51. Press MF, Bernstein L, Thomas PA et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol 1997;15:2894-2904.
52. Ross JS, Muraca PJ, Jaffe D et al. Multivariate analysis of prognostic factors in lymph node negative breast cancer. Mod Pathol 1998;11:26A.
53. Depowski PL, Brien TP, Sheehan CE et al. Prognostic significance of p34cdc2 cyclin-dependent kinase and MIB1 overexpression, and HER-2/neu gene amplification detected by fluorescence in situ hybridization in breast cancer. Am J Clin Pathol 1999;112:459-469.
54. Querzoli P, Albonico G, Ferretti S et al. Modulation of biomarkers in minimal breast carcinoma: a model for human breast carcinoma progression. Cancer 1998;83:89-97.
55. Andrulis IL, Bull SB, Blackstein ME et al. neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto Breast Cancer Study Group. J Clin Oncol 1998;16:1340-1349.
56. Sjogren S, Inganas M, Lindgren A et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol 1998;16:462-469.
57. Harbeck N, Ross JS, Yurdseven S et al. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol 1999;14:663-671.
58. Scorilas A, Yotis J, Pateras C et al. Predictive value of c-erbB-2 and cathepsin-D for Greek breast cancer patients using univariate and multivariate analysis. Clin Cancer Res 1999;5:815-821.
59. Rudolph P, Olsson H, Bonatz G et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol 1999;187:207-216.
60. Reed W, Hannisdal E, Boehler PJ et al. The prognostic value of p53 and c-erb B-2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariate analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer 2000;88:804-813.
61. Pauletti G, Dandekar S, Rong H et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000;18:3651-3664.
62. Kakar S, Puangsuvan N, Stevens JM et al. HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: comparison of results and correlation with survival. Mol Diagn 2000;5:199-207.
63. Agrup M, Stal O, Olsen K et al. C-erbB-2 overexpression and survival in early onset breast cancer. Breast Cancer Res Treat 2000;63:23-29.
64. Umekita Y, Ohi Y, Sagara Y et al. Co-expression of epidermal growth factor receptor and transforming growth factor-alpha predicts worse prognosis in breast-cancer patients. Int J Cancer 2000;89:484-487.
65. Pawlowski V, Revillion F, Hebbar M et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000;6:4217-4225.
66. Volpi A, De Paola F, Nanni O et al. Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 2000;63:181-192.
67. Carr JA, Havstad S, Zarbo RJ et al. The association of HER-2/neu amplification with breast cancer recurrence. Arch Surg 2000;135:1469-1474.
68. Ferrero-Pous M, Hacene K, Bouchet C et al. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 2000;6:4745-4754.
69. Platt-Higgins AM, Renshaw CA, West CR et al. Comparison of the metastasis-inducing protein S100A4 (p9ka) with other prognostic markers in human breast cancer. Int J Cancer 2000;89:198-208.
70. Eppenberger-Castori S, Kueng W, Benz C et al. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645-656.
71. Jukkola A, Bloigu R, Soini Y et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer 2001;37:347-354.
72. Gaci Z, Bouin-Pineau MH, Gaci M et al. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors. Int J Oncol 2001;18:793-800.
73. Rudolph P, Alm P, Olsson H et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol 2001;32:311-319.
74. Beenken SW, Grizzle WE, Crowe DR et al. Molecular biomarkers for breast cancer prognosis: coexpression of c-erbB-2 and p53. Ann Surg 2001;233:630-638.
75. +) breast cancer patients with poor prognosis. Ann Oncol 2001;12:525-533.
76. Riou G, Mathieu MC, Barrois M et al. c-erbB-2 (HER-2/neu) gene amplification is a better indicator of poor prognosis than protein over-expression in operable breast-cancer patients. Int J Cancer 2001;95:266-270.
77. Horita K, Yamaguchi A, Hirose K et al. Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer. Eur J Histochem 2001;45:73-84.
78. Suo Z, Risberg B, Kalsson MG et al. EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 2002;196:17-25.
79. Ristimaki A, Sivula A, Lundin J et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635.
80. Rosenthal SI, Depowski PL, Sheehan CE et al. Comparison of HER-2/neu oncogene amplification detected by fluorescence in situ hybridization in lobular and ductal breast cancer. Appl Immunohistochem Mol Morphol 2002;10:40-46.
81. Tsutsui S, Ohno S, Murakami S et al. Prognostic value of c-erbB2 expression in breast cancer. J Surg Oncol 2002;79:216-223.
82. Spizzo G, Obrist P, Ensinger C et al. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer. Int J Cancer 2002;98:883-888.
83. Kato T, Kameoka S, Kimura T et al. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer. Anticancer Res 2002;22:1097-1103.
84. el-Ahmady O, el-Salahy E, Mahmoud M et al. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up. Anticancer Res 2002;22:2493-2499.
85. Joensuu H, Isola J, Lundin M et al. Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pTIN0M0 breast cancer: a nationwide population-based study. Clin Cancer Res 2003;9:923-930.
86. Schnitt SJ, Jacobs TW. Current status of HER2 testing: caught between a rock and a hard place. Am J Clin Pathol 2001;116:806-810.
87. Hayes DF, Thor AD. c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 2002;29:231-245.
88. Masood S, Bui MM. Prognostic and predictive value of HER2/neu oncogene in breast cancer. Microsc Res Tech 2002;59:102-108.
89. Press MF, Hung G, Godolphin W et al. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res 1994;54:2771-2777.
90. Paik S, Bryant J, Tan-Chiu E et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
91. Paik S, Tan-chui E, Bryan J et al. Successful quality assurance program for HER-2 testing in the NSABP trial for Herceptin. Breast Cancer Res Treat 2002;76(suppl 1): S31.
92. Roche PC, Suman VJ, Jenkins RB et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.
93. Rhodes A, Jasani B, Anderson E et al. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002;118:408-417.
94. Wang S, Saboorian MH, Frenkel EP et al. Assessment of HER-2/neu status in breast cancer. Automated Cellular Imaging System (ACIS)-assisted quantitation of immunohistochemical assay achieves high accuracy in comparison with fluorescence in situ hybridization assay as the standard. Am J Clin Pathol 2001;116:495-503.
95. Bloom KJ, Torre-Bueno J, Press M et al. Comparison of HER-2/neu analysis using FISH and IHC when HercepTest is scored using conventional microscopy and image analysis. Breast Cancer Res Treat 2000;64:99.
96. Wang S, Saboorian MH, Frenkel E et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridization assays. J Clin Pathol 2000;53:374-381.
97. Tanner M, Gancberg D, Di Leo A et al. Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000;157:1467-1472.
98. Zhao J, Wu R, Au A et al. Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma. Mod Pathol 2002;15:657-665.
99. Pawlowski V, Revillion F, Hornez L et al. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer. Cancer Detect Prev 2000;24:212-223.
100. Bieche I, Onody P, Laurendeau I et al. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications. Clin Chem 1999;45:1148-1156.
101. Tubbs RR, Pettay JD, Roche PC et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:2714-2721.
102. Huston JS, George AJ. Engineered antibodies take center stage. Hum Antibodies 2001;10:127-142.
103. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001;28:43-47.
104. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002;62:209-243.
105. Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002;1:117-123.
106. Ligibel JA, Winer EP. Trastuzumab/chemotherapy combinations in metastatic breast cancer. Semin Oncol 2002;29(suppl 11):38-43.
107. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
108. Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002;29(suppl 11):22-28.
109. HercepTest package insert. Glostrup Denmark: Dako Corporation.
110. Roche PC, Ingle JN. Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol 1999;17:434.
111. Mass RD, Press MF, Anderson S et al. Improved survival benefit from Herceptin (trastuzumab) in patients selected by fluorescence in situ hybridization (FISH). Proc Am Soc Clin Oncol 2001;20:85.
112. Vogel CL, Cobleigh MA, Tripathy D et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-726.
113. Seidman AD, Fornier MN, Esteva FJ et al. Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 2001;19:2587-2595.
114. Fornier M, Risio M, Van Poznak C et al. HER2 testing and correlation with efficacy in trastuzumab therapy. Oncology (Huntingt) 2002;16:1340-1348, 1351-1352; discussion 1352, 1355-1358.
115. Nichols DW, Wolff DJ, Self S et al. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci 2002;32:3-11.
116. Yaziji H, Gown AM. Testing for HER-2/neu in breast cancer: is fluorescence in situ hybridization superior in predicting outcome? Adv Anat Pathol 2002;9:338-344.
117. Press MF, Slamon DJ, Flom KJ. Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens. J Clin Oncol 2002;20:3095-3105.
118. Bilous M, Dowsett M, Hanna W et al. Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol 2003;16:173-182.
119. Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocr Relat Cancer 2001;8:191-195.
120. Muss HB. Role of adjuvant endocrine therapy in early-stage breast cancer. Semin Oncol 2001;28:313-321.
121. Schmid P, Wischnewsky MB, Sezer O et al. Prediction of response to hormonal treatment in metastatic breast cancer. Oncology 2002;63:309-316.
122. Nunes RA, Harris LN. The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 2002;3:125-135; discussion 136-137.
123. Konecny G, Pauletti G, Pegram M et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 2003;95:142-153.
124. Carlomagno C, Perrone F, Gallo C et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without ancillary lymph node metastases. J Clin Oncol 1996;14:2702-2708.
125. Burke HB, Hoang A, Iglehart JD et al. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma. Cancer 1998;82:874-877.
126. Elledge RM, Green S, Ciocca D et al. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group study. Clin Cancer Res 1998;4:7-12.
127. De Placido S, De Laurentiis M, Carlomagno C et al. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-1046.
128. Ravdin PM, Green S, Albain V et al. Initial report of the SWOG biological correlative study of c-ERBB2 expression as a predictor of outcome in a trial comparing adjuvant CAF with Tamoxifen alone. Proc Am Soc Clin Oncol 1998;17:97a.
129. Ellis MJ, Coop A, Singh B et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-3816.
130. Berns EM, Foekens JA, van Staveren IL et al. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11-18.
131. Sparano JA. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin Breast Cancer 2000;1:32-40; discussion 41-42.
132. Yu D. Mechanisms of ErbB2-mediated paclitaxel resistance and trastuzumab-mediated paclitaxel sensitization in ErbB2-overexpressing breast cancers. Semin Oncol 2001;28(suppl 16):12-17.
133. Menard S, Valagussa P, Pilotti S et al. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329-335.
134. Van Poznak C, Tan L, Panageas KS et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326.
135. Baselga J, Seidman AD, Rosen PP et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt) 1997;11 (suppl 2):43-48.
136. Kim R, Tanabe K, Uchida Y et al. The role of HER-2 oncoprotein in drug-sensitivity in breast cancer (review). Oncol Rep 2002;9:3-9.
137. Hamilton A, Larsimont D, Paridaens R et al. A study of the value of p53, HER2, and Bcl-2 in the prediction of response to doxorubicin and paclitaxel as single agents in metastatic breast cancer: a companion study to EORTC 10923. Clin Breast Cancer 2000;1:233-240; discussion 241-242.
138. Di Leo A, Larsimont D, Gancberg D et al. HER-2 and topoisomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol 2001;12:1081-1089.
139. Petit T, Borel C, Ghnassia JP et al. Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. Clin Cancer Res 2001;7:1577-1581.
140. Harris LN, Yang L, Liotcheva V et al. Induction of topoisomerase II activity after ErbB2 activation is associated with a differential response to breast cancer chemotherapy. Clin Cancer Res 2001;7:1497-1504.
141. Pegram MD, Finn RS, Arzoo K et al. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells. Oncogene 1997;15:537-547.
142. Jarvinen TA, Holli K, Kuukasjarvi T et al. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br J Cancer 1998;77:2267-2273.
143. Depowski PL, Rosenthal SI, Brien TP et al. Topoisomerase IIalpha expression in breast cancer: correlation with outcome variables. Mod Pathol 2000;13:542-547.
144. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000;156:839-847.
145. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res 2001;61:5345-5348.
146. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res 2002;8:1107-1116.
147. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin Cancer Res 2002;8:1061-1067.
148. Haffty BG, Brown F, Carter D et al. Evaluation of HER-2 neu oncoprotein expression as a prognostic indicator of local recurrence in conservatively treated breast cancer: a case-control study. Int J Radiat Oncol Biol Phys 1996;35:751-757.
149. Yamauchi H, O'Neill A, Gelman R et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol 1997;15:2518-2525.
150. Isola JJ, Holli K, Oksa H et al. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer. Cancer 1994;73:652-658.
151. Andersen TI, Paus E, Nesland JM et al. Detection of c-erbB-2 related protein in sera from breast cancer patients. Relationship to ERBB2 gene amplification and c-erbB-2 protein overexpression in tumour. Acta Oncol 1995;34:499-504.
152. Willsher PC, Beaver J, Pinder S et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat 1996;40:251-255.
153. Fehm T, Maimonis P, Weitz S et al. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res Treat 1997;43:87-95.
154. Mansour OA, Zekri AR, Harvey J et al. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res 1997;17:3101-3106.
155. Disis ML, Pupa SM, Gralow JR et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367.
156. Krainer M, Brodowicz T, Zeillinger R et al. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology 1997;54:475-481.
157. Fehm T, Maimonis P, Katalinic A et al. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology 1998;55:33-38.
158. Mehta RR, McDermott JH, Hieken TJ et al. Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. J Clin Oncol 1998;16:2409-2416.
159. Colomer R, Montero S, Lluch A et al. Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer. Clin Cancer Res 2000;6:2356-2362.
160. Bewick M, Conlon M, Gerard S et al. HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support. Bone Marrow Transplant 2001;27:847-853.
161. Harris LN, Liotcheva V, Broadwater G et al. Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy. J Clin Oncol 2001;19:1698-1706.
162. All SM, Leitzel K, Chinchilli VM et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem 2002;48:1314-1320.
163. Classen S, Kopp R, Possinger K et al. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy. Tumour Biol 2002;23:70-75.
164. Lipton A, Ali SM, Leitzel K et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002;20:1467-1472.
165. Kandl H, Seymour L, Bezwoda WR. Soluble c-erbB-2 fragments in serum correlates with disease stage and predicts for shortened survival in patients with early-stage and advanced breast cancer. Br J Cancer 1994;70:739-742.
166. Volas GH, Leitzel K, Teramoto Y et al. Serial serum c-erbB-2 levels in patients with breast carcinoma. Cancer 1996;78:267-272.
167. Revillion F, Hebbar M, Boneterre J et al. Plasma c-erbB2 concentrations in relation to chemotherapy in breast cancer patients. Eur J Cancer 1996;32A:231-234.
168. Slamon D, Pegram M. Rationale for trastuzumab (Herceptin®) in adjuvant breast cancer trials. Semin Oncol 2001;28(suppl 3):13-19.
169. Esteva FJ, Valero V, Booser D et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:1800-1808.
170. Bose S, Lesser ML, Norton L et al. Immunophenotype of intraductal carcinoma. Arch Pathol Lab Med 1996;120:81-85.
171. Moreno A, Lloveras B, Figueras A et al. Ductal carcinoma in situ of the breast: correlation between histologic classification and biologic markers. Mod Pathol 1997;10:1088-1092.
172. Mack L, Kerkvliet N, Doig G et al. Relationship of a new histological categorization of ductal carcinoma in situ of the breast with size and the immunohistochemical expression of p53, C-erbB2, bcl-2, and ki-67. Hum Pathol 1997;28:974-979.
173. Wolber RA, Dupuis BA, Wick MR. Expression of c-erbB-2 oncoprotein in mammary and extramammary Paget's disease. Am J Clin Pathol 1991;96:243-247.
174. Fu W, Lobocki CA, Silberberg BK et al. Molecular markers in Paget disease of the breast. J Surg Oncol 2001;77:171-178.
175. Masood S, Bui MM. Assessment of Her-2/neu overexpression in primary breast cancers and their metastatic lesions: an immunohistochemical study. Ann Clin Lab Sci 2000;30:259-265.
176. Dittadi R, Zancan M, Perasole A et al. Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay. Int J Biol Markers 2001;16:255-261.
177. Simon R, Nocito A, Hubscher T et al. Patterns of her-2/neu amplification and overexpression in primary and metastatic breast cancer. J Natl Cancer Inst 2001;93:1141-1146.
178. Vincent-Salomon A, Jouve M, Genin P et al. HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic process. Cancer 2002;94:2169-2173.
179. Xu R, Perle MA, Inghirami G et al. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material. Mod Pathol 2002;15:116-124.
180. Symmans WF, Liu J, Knowles DM et al. Breast cancer heterogeneity: evaluation of clonality in primary and metastatic lesions. Hum Pathol 1995;26:210-216.
181. Gattuso P, Reddy VB, Green LK et al. Prognostic factors for carcinoma of the male breast. Int J Surg Pathol 1995;2:199-206.
182. Joshi MG, Lee AK, Loda M et al. Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 1996;77:490-498.
183. Pich A, Margaria E, Chiusa L. Oncogenes and male breast carcinoma: c-erbB-2 and p53 coexpression predicts a poor survival. J Clin Oncol 2000;18:2948-2956.
184. Wang-Rodriguez J, Cross K, Gallagher S et al. Male breast carcinoma: correlation of ER, PR, Ki-67, Her2-Neu, and p53 with treatment and survival, a study of 65 cases. Mod Pathol 2002;15:853-861.
185. Rayson D, Erlichman C, Suman VJ et al. Molecular markers in male breast carcinoma. Cancer 1998;83:1947-1955.
186. Shpitz B, Bomstein Y, Sternberg A et al. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer. J Surg Oncol 2000;75:252-257.
187. Bloom KJ, Govil H, Gattuso P et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001;182:389-392.
188. Stark A, Hulka BS, Joens S et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol 2000;18:267-274.
189. Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 2001;6:393-406.
190. Piccart M, Lohrisch C, Di Leo A et al. The predictive value of HER2 in breast cancer. Oncology 2001;61(suppl 2):73-82.
191. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001;61 (suppl 2):1-13.
192. DiGiovanna MP, Stem DF. Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor. Cancer Res 1995;55:1946-1955.
193. Thor AD, Liu S, Edgerton S et al. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 2000;18:3230-3239.
194. DiGiovanna MP, Chu P, Davison TL et al. Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates. Cancer Res 2002;62:6667-6673.